Freestone Grove Partners’s CareDx CDNA Stock Holding History

Freestone Grove Partners’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,416	Closed	-$76.7K	–	1063
2026 Q1	$76.7K	Buy	+4,416	New	+$83.6K	﹤0.01%	818
2025 Q4	–	Sell	-19,678	Closed	-$286K	–	756
2025 Q3	$286K	Buy	+19,678	New	+$281K	﹤0.01%	616
2025 Q1	–	Sell	-14,620	Closed	-$313K	–	611
2024 Q4	$313K	Buy	+14,620	New	+$356K	﹤0.01%	463

Other funds holding CDNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's CDNA Position: Q2 2026 in Review

Freestone Grove Partners sold out of CareDx (CDNA) in Q2 2026, closing a stake of 4,416 shares — an estimated $76.7K sold.

Freestone Grove Partners first reported a position in CDNA in Q4 2024 and held it in 3 quarters. The position peaked at $313K in Q4 2024. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

Freestone Grove Partners reported no remaining CareDx position as of Q2 2026 after selling out during the quarter.
Freestone Grove Partners sold 4,416 CareDx shares in Q2 2026, an estimated $76.7K.
Freestone Grove Partners first reported a position in CareDx in Q4 2024 and held it in 3 quarters.
Freestone Grove Partners's CareDx position peaked at $313K in Q4 2024.
227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.